



**BlueCross
BlueShield**

Federal Employee Program.

Blue Cross Blue Shield Association
750 9th St NW, Suite 900
Washington, D.C. 20001
1-800-624-5060
Fax 1-877-378-4727

5.40.040

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Cardiovascular Agents	Original Policy Date:	December 19, 2025
Subject:	Redemplo	Page:	1 of 4

Last Review Date: March 6, 2026

Redemplo

Description

Redemplo (plozasiran)

Background

Redemplo (plozasiran) is a small interfering ribonucleic acid (siRNA) conjugated with GalNAc that degrades the apolipoprotein C-III (apoC-III) mRNA through the RNA interference mechanism resulting in reduced levels of hepatic and serum apoC-III protein. Reduction of apoC-III protein leads to increased clearance of serum triglycerides (1).

Regulatory status

FDA-approved indication: Redemplo is an apolipoprotein C-III (apoC-III)-directed small interfering ribonucleic acid (siRNA) indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) (1).

The safety and effectiveness of Redemplo in pediatric patients less than 18 years of age have not been established (1).

Related policies

Tryngolza

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Redemplo may be considered **medically necessary** if the conditions indicated below are met.

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Cardiovascular Agents	Original Policy Date:	December 19, 2025
Subject:	Redemplo	Page:	2 of 4

Redemplo may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Familial chylomicronemia syndrome (FCS)

AND ALL of the following:

1. Patient has **ONE** of the following:
 - a. Diagnosis confirmed by genetic testing documenting biallelic pathogenic variants in FCS-causing genes (e.g., LPL, GPIHBP1, APOA5, APO2, LMF1, GPD1, CREB3L3)
 - b. North American familial syndrome (NAFCS) score ≥ 45 **OR** Moulin score ≥ 10
(e.g., <https://tryngolzahcp.com/diagnosing-fcs/fcs-diagnostic-scoring?tab=nafcs>, <https://tryngolzahcp.com/diagnosing-fcs/fcs-diagnostic-scoring?tab=moulin>)
2. Fasting triglyceride (TG) levels ≥ 880 mg/dL
3. Used in combination with a low-fat diet (≤ 20 g of fat per day)
4. **NO** dual therapy with Tryngolza (olezarsen)

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Familial chylomicronemia syndrome (FCS)

AND ALL of the following:

1. Reduction in fasting triglycerides from baseline

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Cardiovascular Agents	Original Policy Date:	December 19, 2025
Subject:	Redemplo	Page:	3 of 4

2. Used in combination with a low-fat diet (≤ 20 g of fat per day)
3. **NO** dual therapy with Tryngolza (olezarsen)

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity 1 prefilled syringe per 84 days

Duration 12 months

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Redemplo is an apoC-III-directed siRNA indicated to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). The safety and effectiveness of Redemplo in pediatric patients less than 18 years of age have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Redemplo while maintaining optimal therapeutic outcomes.

References

1. Redemplo [package insert]. Pasadena, CA: Arrowhead Pharmaceuticals, Inc.; November 2025.

Policy History

Date	Action
December 2025	Addition to PA
March 2026	Annual review. Per SME, added option of NAFCS or Moulin score instead of genetic confirmation

Keywords

5.40.040

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Cardiovascular Agents	Original Policy Date:	December 19, 2025
Subject:	Redemplo	Page:	4 of 4

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 6, 2026 and is effective on April 1, 2026.